Telix Pharmaceuticals (TLX) Total Current Liabilities (2023 - 2025)
Telix Pharmaceuticals (TLX) has disclosed Total Current Liabilities for 3 consecutive years, with $231.6 million as the latest value for Q4 2025.
- Quarterly Total Current Liabilities rose 7.03% to $231.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $231.6 million through Dec 2025, up 7.03% year-over-year, with the annual reading at $231.6 million for FY2025, 12.94% up from the prior year.
- Total Current Liabilities for Q4 2025 was $231.6 million at Telix Pharmaceuticals, up from $216.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $231.6 million in Q4 2025, with the low at $107.5 million in Q4 2023.
- Average Total Current Liabilities over 3 years is $185.2 million, with a median of $216.4 million recorded in 2024.
- The sharpest move saw Total Current Liabilities surged 101.39% in 2024, then rose 7.03% in 2025.
- Over 3 years, Total Current Liabilities stood at $107.5 million in 2023, then soared by 101.39% to $216.4 million in 2024, then increased by 7.03% to $231.6 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods came in at $231.6 million, $216.4 million, and $107.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.